Cat. No. 5062
Biological ActivityAntagonist of TrkB receptors; inhibits BDNF-induced TrkB activity (IC50 = 0.30 nM). Allosterically alters TrkB receptor conformation but does not alter BDNF binding. Prevents BDNF-induced cold allodynia in mice. Also shown to exhibit putative anxiolytic properties in mice.
(Modifications: Disulfide bridge between 1 - 11)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Constandil et al (2012) Cyclotraxin-B, a new TrkB antagonist, and glial blockade by propentofylline, equally prevent and reverse cold allodynia induced by BDNF or partial infraorbital nerve constriction in mice. J.Pain 13 579. PMID: 22560237.
Cazorla et al (2010) Cyclotraxin-B, the first highly potent and selective TrkB antagonist, has anxiolytic properties in mice. PLoS One 5 e9777. PMID: 20333308.
If you know of a relevant reference for Cyclotraxin B please let us know.
Citations are publications that use Tocris products. Selected citations for Cyclotraxin B include:
Zhong et al (2015) BDNF interacts with endocannabinoids to regulate cocaine-induced synaptic plasticity in mouse midbrain dopamine neurons. Oncotarget 35 4469. PMID: 25762688.
Do you know of a great paper that uses Cyclotraxin B from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Cyclotraxin B, supplier, anxiolytic, antagonists, TrkB, receptors, Tocris Bioscience, Trk Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Potent and selective PDGFR inhibitorGSK 1363089
Potent inhibitor of MET, VEGFR2, Ron and AXLPF 06273340
Potent and selective pan-Trk inhibitor; peripherally restricted
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.